Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Data Shed Further Light on HCV Protease Race

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Final Phase II data have set the stage for the ultimate chapter in a compelling race to develop the first hepatitis C protease inhibitor. These first-generation molecules - Vertex's telaprevir and Schering-Plough's boceprevir - are not perfect, but look likely to significantly improve HCV cure rates and establish shorter durations for difficult-to-take therapeutic regimens

You may also be interested in...



INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo

Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark.

Merck Protease Inhibitor Impresses At EASL, Anadys Suffers Rash Concerns

The second-generation protease inhibitors for hepatitis C could have a tough time competing with the lead agents in the class, Vertex's telaprevir and Schering-Plough's boceprevir - as data presented at the European Association for the Study of the Liver's recent meeting reveals safety problems with some of the products in earlier stage development

Merck Protease Inhibitor Impresses At EASL, Anadys Suffers Rash Concerns

The second-generation protease inhibitors for hepatitis C could have a tough time competing with the lead agents in the class, Vertex's telaprevir and Schering-Plough's boceprevir - as data presented at the European Association for the Study of the Liver's recent meeting reveals safety problems with some of the products in earlier stage development

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel